As a particularly aggressive subtype, triple negative breast cancer (TNBC) has been regarded as the most challenging breast cancer without hormone receptors and human epidermal growth factor receptor 2 (HER2) gene amplification, which commonly results in greater metastatic potential, higher rates of relapse, together with shorter overall survival compared with other subtypes (3). This evidence concerns the gene ERBB2 and breast cancer.